RESEARCH ARTICLE
Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants Margaret McManus1, Eric Mick2, Richard Hudson1, Lynne M. Mofenson3, John L. Sullivan1, Mohan Somasundaran1, Katherine Luzuriaga1*, PACTG 356 Investigators¶
a11111
1 Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 2 Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 3 The Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America ¶ Membership of the Pediatric ACTG (PACTG) 356 Investigators are listed in the Acknowledgments. *
[email protected]
OPEN ACCESS Citation: McManus M, Mick E, Hudson R, Mofenson LM, Sullivan JL, Somasundaran M, et al. (2016) Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. PLoS ONE 11(4): e0154391. doi:10.1371/journal.pone.0154391 Editor: Nicolas Sluis-Cremer, University of Pittsburgh, UNITED STATES Received: February 18, 2016 Accepted: April 12, 2016 Published: April 22, 2016 Copyright: © 2016 McManus et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and the figures. Funding: This work was supported by National Institutes of Health grants AI32907, K24-HD01489, the University of Massachusetts Center for AIDS Research (AI428845), and the University of Massachusetts Center for Clinical and Translational Science (UL1-TR001453) to Katherine Luzuriaga. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the
Abstract The primary aim of this study was to measure HIV-1 persistence following combination antiretroviral therapy (cART) in infants and children. Peripheral blood mononuclear cell (PBMC) HIV-1 DNA was quantified prior to and after 1 year of cART in 30 children, stratified by time of initiation (early, age 3 months-2 years, LT). Pre-therapy PBMC HIV-1 DNA levels correlated with pre-therapy plasma HIV-1 levels (r = 0.59, p
